FDA approves ZANVASTRO as first disease-modifying therapy for Alexander disease
ZANVASTRO (zilganersen) is now FDA-approved as the first disease-modifying therapy for Alexander disease in both children and adults, citing pivotal trial data showing motor function stabilization and a favorable safety profile.
ZANVASTRO (zilganersen) is now FDA-approved as the first disease-modifying therapy for Alexander disease in both children and adults, supported by pivotal trial data showing significant motor function stabilization and a favorable safety profile.
Launch strategies focus on patient transition, acces…